discovery chemistry
From Our Labs to the Clinic & Market
The real-world impact of o2h Discovery’s scientific contributions – translating partner programmes from early chemistry into the clinic and onto the market.
Spotlight – Deep o2h Engagements now in the clinic or market
METTL3 inhibitor programme → B1-9321 in Phase 1/2 AML
Chemistry FTE from lead generation through to scale-up
ATR kinase inhibitor → Phase 1/2 in oncology
Chemistry & biology from lead optimisation to candidate
RNA-targeted small molecules → multiple Phase 1 assets
57 FTEs - 4 o2h-synthesised compounds in Arrakis patents
Multiple GPCR programmes → HTL0016878 in Phase 2
MMR pathway chemistry → NEO-201 Phase 1 oncology
Chemistry FTE, FFS, DMPK, PROTAC & scale-up
Karyopharm
MARKETED
XPO1 inhibitor lead opt → Xpavia (selinexor), FDA 2019